"The voice for cancer physicians and their patients in Massachusetts."

FDA Approval of a new dosing regimen for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)

21 Nov 2022 11:37 AM | Katy Monaco (Administrator)

FDA approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz Pharmaceuticals). Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. It also is approved to be administered every 48 hours at a dose of 25 mg/m2 intramuscularly.  Read More.


Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software